Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- QUBT +24.2%, PACS +20.1%, SIBN +16.4%, TE +16.1%, HLIT +14.7%, DSP +13.6%, ZBRA +13.4%, SE +10.6%, CDNL +10%, EIKN +8.8% (also provides clinical updates), VG +8.8%, HLIO +8.3%, PLUG +6.8%, TME +6.6%, VSTS +6%, ARMK +5.5%, RAL +5.4%, SGHC +5.1%, RGTI +4.5%, HALO +4.4%, ESOA +4.1%, QBTS +4%, FIGR +3.9%, AMTM +3.6%, NOVT +3.6%, STE +3.1% (also authorizes new share repurchase program), BETA +3%, ODV +3%, ARVN +2.9%, GPRO +2.3%, NVRI +1.2%, Q +1.2%, OVV +1.1%
Other news:
- MGNX +19.3% (to sell GMP manufacturing operations to Bora Pharmaceuticals)
- RIGL +6.9% (Exclusive Global Licensing Agreement for VEPPANU (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer)
- LOT +4.3% (outlines Focus 2030 strategy centered on hybrid expansion and profitability targets)
- ALHC +4.1% (to join S&P SmallCap 600)
- LIEN +3.2% ($500 mln mixed securities shelf offering)
- QGEN +2.1% (proposes higher shareholder returns and continued board refresh at 2026 AGM)
- CTNM +2% (two posters at ATS 2026 International Conference)
- NVO +2% (highlights additional STEP UP data for higher-dose Wegovy)
- PSN +1.5% (CEO insider purchase)
- GPK +1.3% (discloses insider purchase)
- IREN +1% (prices offering of $2.6 bln aggregate principal amount of 1.00% convertible senior notes due 2033)
- ESLT +0.9% (receives $212 mln U.S. Army night vision order)